ARWR - Arrowhead Pharmaceuticals - Stock & Dividends

Arrowhead Pharmaceuticals Inc. is a biotech company that focuses on developing innovative medicines to tackle complex and debilitating diseases in the United States. Their pipeline is packed with promising candidates, including Plozasiran, which is in late-stage clinical trials to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome - all serious conditions that affect lipid metabolism.

Zodasiran, another key candidate, is being tested in Phase 2b clinical trials to address dyslipidemia and hypertriglyceridemia, while ARO-PNPLA3 is in early-stage trials to treat non-alcoholic steatohepatitis, a common liver disease. The company is also exploring ARO-RAGE to combat inflammatory pulmonary conditions, and ARO-MUC5AC to tackle muco-obstructive pulmonary diseases.

In addition, Arrowhead is investigating ARO-MMP7 for idiopathic pulmonary fibrosis, a chronic and debilitating lung disease. They're also working on ARO-DUX4 to treat facioscapulohumeral muscular dystrophy, a genetic disorder that affects muscle strength and movement. Furthermore, ARO-SOD1 is being developed to potentially treat amyotrophic lateral sclerosis, a devastating neurological disease. And, ARO-C3 is in early-stage trials to address various complement-mediated or associated renal diseases.

Beyond these internal programs, Arrowhead is collaborating with major pharmaceutical companies on several projects. For instance, they're co-developing JNJ-3989 with Janssen Pharmaceuticals to treat chronic hepatitis B virus infection. They're also working with Glaxosmithkline on Olpasiran, which is in Phase 3 trials to reduce apolipoprotein A production. Additionally, they're partnering with Horizon Therapeutics on HZN-457 to treat uncontrolled gout, and with Amgen on Fazirsiran to address liver disease associated with alpha-1 antitrypsin deficiency.

With a strong foundation in RNA-based therapies, Arrowhead Pharmaceuticals has established a robust network of partnerships with industry leaders, including Takeda Pharmaceutical Company Limited and Glaxosmithkline Intellectual Property (No. 3) Limited. Founded in 2003, the company is headquartered in Pasadena, California, and is committed to bringing innovative treatments to patients with unmet medical needs.